NVTA vs. ACON, ACOR, AKAN, SINT, BBLG, EVLO, EVFM, SPRC, SIENQ, and SCNI
Should you be buying Invitae stock or one of its competitors? The main competitors of Invitae include Aclarion (ACON), Acorda Therapeutics (ACOR), Akanda (AKAN), Sintx Technologies (SINT), Bone Biologics (BBLG), Evelo Biosciences (EVLO), Evofem Biosciences (EVFM), SciSparc (SPRC), Sientra (SIENQ), and Scinai Immunotherapeutics (SCNI). These companies are all part of the "medical" sector.
Aclarion (NASDAQ:ACON) and Invitae (NYSE:NVTA) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, earnings, media sentiment, valuation, dividends, profitability, risk, analyst recommendations and community ranking.
Invitae received 450 more outperform votes than Aclarion when rated by MarketBeat users. However, 100.00% of users gave Aclarion an outperform vote while only 60.95% of users gave Invitae an outperform vote.
In the previous week, Invitae had 6 more articles in the media than Aclarion. MarketBeat recorded 8 mentions for Invitae and 2 mentions for Aclarion. Invitae's average media sentiment score of 1.43 beat Aclarion's score of 0.20 indicating that Aclarion is being referred to more favorably in the media.
7.5% of Aclarion shares are owned by institutional investors. Comparatively, 61.3% of Invitae shares are owned by institutional investors. 22.3% of Aclarion shares are owned by company insiders. Comparatively, 0.7% of Invitae shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Aclarion has higher earnings, but lower revenue than Invitae.
Aclarion has a beta of 0.44, indicating that its share price is 56% less volatile than the S&P 500. Comparatively, Invitae has a beta of 1.59, indicating that its share price is 59% more volatile than the S&P 500.
Invitae has a consensus price target of $1.00, indicating a potential upside of 99,900.00%. Given Aclarion's higher possible upside, analysts plainly believe Invitae is more favorable than Aclarion.
Invitae has a net margin of -299.14% compared to Invitae's net margin of -6,480.47%. Invitae's return on equity of -724.93% beat Aclarion's return on equity.
Summary
Invitae beats Aclarion on 8 of the 14 factors compared between the two stocks.
Get Invitae News Delivered to You Automatically
Sign up to receive the latest news and ratings for NVTA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding NVTA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
